1 1

Dima Biotech

PME101256

Human FCRL2 Protein, His Tag

Human FCRL2 Protein, His Tag

$389.00 USD
$389.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Target
Uniprot ID
PRODUCT DATA
TARGET

SYNONYMS

CD307b;FCRH2;IFGP4;IRTA4;SPAP1;SPAP1A;SPAP1B;SPAP1C
DESCRIPTION

Recombinant Human FCRL2 Protein with C-terminal 6×His tag
DELIVERY

In Stock
UNIPROT ID

Q96LA5
EXPRESSION HOST

HEK293
TAG

C-6×His Tag
MOLECULAR CHARACTERIZATION

FCRL2(Leu20-Thr398) 6×His tag
MOLECULAR WEIGHT

The protein has a predicted molecular mass of 42.2 kDa after removal of the signal peptide. The apparent molecular mass of FCRL2-His is approximately 55-70 kDa due to glycosylation.
PURITY

The purity of the protein is greater than 85% as determined by SDS-PAGE and Coomassie blue staining.
FORMULATION & RECONSTITUTION

Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
STORAGE & SHIPPING

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
BACKGROUND

This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein has four extracellular C2-type immunoglobulin domains, a transmembrane domain and a cytoplasmic domain that contains one immunoreceptor-tyrosine activation motif and two immunoreceptor-tyrosine inhibitory motifs. This protein may be a prognostic marker for chronic lymphocytic leukemia. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Apr 2009]
USAGE

Research use only
IMAGES

sp-PME101256 FCRL2 Fig.1 SDS PAGE 1
Figure 1.Human FCRL2 Protein, His Tag on SDS-PAGE under reducing condition.

View full details